Erasca logo

ErascaNASDAQ: ERAS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 July 2021

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$791.64 M
-63%vs. 3y high
72%vs. sector
-vs. 3y high
-vs. sector
-61%vs. 3y high
53%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 22:04:11 GMT
$2.80+$0.07(+2.56%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

ERAS Latest News

Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
zacks.com15 November 2024 Sentiment: POSITIVE

After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Erasca to Present at Upcoming Investor Conferences
globenewswire.com05 November 2024 Sentiment: POSITIVE

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings.

Erasca Reports Second Quarter 2024 Business Updates and Financial Results
globenewswire.com12 August 2024 Sentiment: POSITIVE

In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors

Should You Buy Erasca, Inc. (ERAS) After Golden Cross?
zacks.com04 June 2024 Sentiment: POSITIVE

After reaching an important support level, Erasca, Inc. (ERAS) could be a good stock pick from a technical perspective. ERAS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
globenewswire.com21 May 2024 Sentiment: POSITIVE

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional shares. All of the shares in the offering were sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, were approximately $184.0 million.

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
globenewswire.com16 May 2024 Sentiment: POSITIVE

The Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are strong oral inhibitors that have the potential to be the top choice for treating RAS-mutated solid tumors.

Erasca Announces Pricing of Underwritten Offering of Common Stock
globenewswire.com16 May 2024 Sentiment: NEUTRAL

Erasca, Inc. (Nasdaq: ERAS), a company focused on developing therapies for RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at $1.85 per share. The offering, expected to raise approximately $160 million before expenses, is set to close on May 21, 2024. Additionally, Erasca has granted the underwriters a 30-day option to purchase up to 12,972,972 additional shares at the offering price.

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
Seeking Alpha29 March 2024 Sentiment: POSITIVE

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire03 January 2024 Sentiment: NEUTRAL

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company on Tuesday, January 9, 2024 at 9:00 am Pacific Time in Elizabethan Room D. Dr. Lim and David M. Chacko, M.D., chief financial officer and chief business officer, will also participate in one-on-one investor meetings.

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
GlobeNewsWire25 May 2023 Sentiment: POSITIVE

Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation of this combination will focus on EC-naïve patients based on promising initial activity

What type of business is Erasca?

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

What sector is Erasca in?

Erasca is in the Healthcare sector

What industry is Erasca in?

Erasca is in the Biotechnology industry

What country is Erasca from?

Erasca is headquartered in United States

When did Erasca go public?

Erasca initial public offering (IPO) was on 16 July 2021

What is Erasca website?

https://www.erasca.com

Is Erasca in the S&P 500?

No, Erasca is not included in the S&P 500 index

Is Erasca in the NASDAQ 100?

No, Erasca is not included in the NASDAQ 100 index

Is Erasca in the Dow Jones?

No, Erasca is not included in the Dow Jones index

When was Erasca the previous earnings report?

No data

When does Erasca earnings report?

The next expected earnings date for Erasca is 28 March 2025